Literature DB >> 7288792

Selection of patients with chronic drug-resistant epilepsy for resective surgery: 5 years' experience.

C E Polkey.   

Abstract

Selection criteria are the key to success in resective surgery for intractable epilepsy. Using such criteria about 50% of patients admitted for assessment are considered unsuitable, half of these for neurophysiological reasons or because there is evidence of more than one area of structural abnormality. Selection for a good result from temporal lobectomy can be judged, both on the proportion of positive pathological lesions in the resected temporal lobes and on a high degree of seizure relief together with a low incidence of side effects. The same holds for other resections. The relationship between these factors is reviewed.

Entities:  

Mesh:

Year:  1981        PMID: 7288792      PMCID: PMC1438896          DOI: 10.1177/014107688107400804

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  5 in total

1.  Infantile hemiplegia treated by removing one cerebral hemisphere.

Authors:  R A KRYNAUW
Journal:  J Neurol Neurosurg Psychiatry       Date:  1950-11       Impact factor: 10.154

2.  Reversibility by temporal-lobe resection of the behavioral abnormalities of temporal-lobe epilepsy.

Authors:  M A Falconer
Journal:  N Engl J Med       Date:  1973-08-30       Impact factor: 91.245

3.  Genetic and related aetiological factors in temporal lobe epilepsy. A review.

Authors:  M A Falconer
Journal:  Epilepsia       Date:  1971-03       Impact factor: 5.864

4.  Surgery for epilepsy.

Authors:  C E Polkey
Journal:  Br J Hosp Med       Date:  1981-01

5.  Selection of patients with intractable epilepsy for resective surgery.

Authors:  C E Polkey
Journal:  Arch Dis Child       Date:  1980-11       Impact factor: 3.791

  5 in total
  1 in total

1.  Effects of anterior temporal lobectomy apart from the relief of seizures: a study of 40 patients.

Authors:  C E Polkey
Journal:  J R Soc Med       Date:  1983-05       Impact factor: 18.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.